China non-life market on road to recovery but margin pressures remain: Fitch
August 19 2022 by Karen Lai
-
China’s ZhongAn’s operating performance is subject to investment volatility, business risk: AM Best
- November 11
The rating agency affirms financial strength rating of A- (excellent) and long-term issuer credit rating of “a-” (excellent) to the carrier with a stable outlook.
-
NZ non-life segment growth to remain robust even as carriers adjust rates: AM Best
- November 11
In its latest report on the segment, the rating agency has maintained a stable outlook citing solid premium growth supported by rate adjustments.
-
Fitch upgrades QBE Insurance as profitability, capital buffer improve
- November 8
The rating agency has affirmed QBE's insurer rating 'A-' taking into account its improving financial performance and solid capitalisation metrics.
-
Fitch downgrades Suncorp Group following banking exit, higher reinsurance retentions
- November 8
The group’s main non-life arm AAI’s financial strength rating has been changed to A+ from AA-.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
